Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 11Active not recruiting 6Unknown 5Recruiting 4Terminated 3Withdrawn 2

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 79Sarcoma 16Gastrointestinal 8Dermatologic 6Tumor-Agnostic 4NET 4Lymphoid 4Endocrine 4Thoracic 3Other solid neoplasm 3Genitourinary 3Gynecologic 2Breast 1

Conditions

Neuroendocrine Tumors 3Gastro-enteropancreatic neuroendocrine tumor 1Frailty 1

Interventions

lutetium Lu 177 dotatate 16Magnetic Resonance Spectroscopy 14gallium Ga 68 dotatate 9Specimen Handling 8Everolimus 8pembrolizumab 7cabozantinib 6Cisplatin 6fluorodopa F 18 5Etoposide 5trametinib 4surufatinib 4lanreotide 4dabrafenib 4cemiplimab 4X-Rays 4Temozolomide 4Nivolumab 4Lutetium-177 4Lutetium 4Fluorodeoxyglucose F18 4Carboplatin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4olaparib 3lenvatinib 3copper dotatate CU-64 3Transurethral Resection of Prostate 3Thyrotropin Alfa 3Surveys and Questionnaires 3Somatostatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Temozolomide × Endocrine × Clear all
NCT04339036 2026-06-04

CapTemY90

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting
70 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT05554003 2024-11-18

MeTe

European Institute of Oncology

Phase 2 Recruiting
46 enrolled
EndocrineNET

Frailty, Neuroendocrine Tumors

NCT06038461 2024-10-01

An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1/2 Recruiting
40 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT04893785 2024-06-18

CABOTEM

National Cancer Institute, Naples

Phase 2 Recruiting
35 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡